Most molecules that drift into a cell end up scattered more or less everywhere. SS-31 is the exception worth paying attention to. It's the laboratory designation for the compound also known as elamipretide, and it was built to do the opposite of scatter: to gather at a single address inside the cell. That address is the mitochondrion — more precisely, its inner membrane. SS-31 is a synthetic four-amino-acid peptide offered strictly for research use only, and this article looks at the chemistry behind its targeting rather than at any use in people or animals. Research-grade SS-31 is a chemical for laboratory study; it is not equivalent to, and should not be confused with, any approved pharmaceutical product bearing the elamipretide name.
Understanding how a peptide is "targeted" turns out to explain most of why its structure looks the way it does. If you're researching this compound, the targeting story is the thread that ties its odd-looking sequence to where it ends up in a cell.
What "mitochondria-targeted" actually means
In one line: a targeted molecule binds something that exists in only one place, so it piles up there instead of spreading out.
Mitochondria are the small compartments inside most of our cells where energy from food is converted into ATP, the molecule cells spend to do work. Each one has two membranes. The inner membrane is folded into pleats called cristae, and that's where the energy-conversion machinery sits — so it's the part of the mitochondrion most of this chemistry cares about.
What sets that inner membrane apart is a chemical signature the rest of the cell mostly lacks: a phospholipid called cardiolipin. Cardiolipin carries a net negative charge and sits almost exclusively in the inner mitochondrial membrane, where it helps hold the cristae and their embedded protein complexes in working order. Since cardiolipin lives in essentially one location, a molecule that binds it effectively carries a postal code for the inner membrane. A 2025 review of the compound's mechanism describes exactly this cardiolipin-directed localization as the heart of how SS-31 behaves (Marcucci et al., 2025). The same logic — a peptide that keys on the mitochondrion — turns up elsewhere in the research literature; for a different example, see our explainer on another peptide tied to the mitochondria.
The four amino acids that make up SS-31
In one line: SS-31 is a tiny peptide whose four building blocks are split evenly between "charged" and "aromatic," and that split is the whole design.
The sequence is written D-Arg–Dmt–Lys–Phe–NH2, and the molecule weighs roughly 639.8 g/mol (Allen & Schenkel, 2025). A few of those notations deserve unpacking in plain terms. The "D-Arg" is a mirror-image (D-form) version of the amino acid arginine; using the D-form makes the peptide harder for the body's ordinary enzymes to chew up, so it stays intact longer in an experimental setting. "Dmt" is dimethyltyrosine, a modified aromatic amino acid. And the "-NH2" at the tail end means the peptide is capped (amidated) — one more tweak that adds stability.
Now the design itself. Two of the four residues — D-Arg and Lys (lysine) — are basic, which means they carry positive charge. The other two — Dmt and Phe (phenylalanine) — are aromatic: they have flat, ring-shaped, oily side chains that like to slip into membranes. So the peptide is, in a sense, half magnet and half grease. That pairing of charge and aromaticity, as we'll see next, is what lets such a small molecule find and stick to the right membrane. Wringing a function out of four carefully chosen residues is a recurring theme in peptide chemistry; the same economy of design shows up in other research tetrapeptides.
How SS-31 finds and binds the inner membrane
In one line: the positive charge pulls SS-31 toward the negatively charged inner membrane, and the aromatic residues anchor it there.
At the pH found inside cells, SS-31 carries a net positive charge of roughly 3+. Opposite charges attract, so the positive peptide is drawn toward the negatively charged, cardiolipin-rich inner membrane. Once it arrives, the aromatic side chains of Dmt and Phe partition into the oily interior of the lipid bilayer, anchoring the peptide at the surface. The payoff is striking: in isolated mitochondria, SS-31 has been reported to concentrate on the order of 5,000-fold relative to the surrounding medium (Allen & Schenkel, 2025). That's a lot of selectivity packed into a four-residue molecule.
The binding is more than passive sticking. A detailed biophysical study showed that SS-31 partitions into anionic lipid bilayers and shifts the electrostatics of the membrane surface, with binding density and affinity scaling directly with the net negative charge of the lipids present (Mitchell et al., 2020). Put plainly: the more cardiolipin-like — the more negatively charged — the membrane, the more tightly SS-31 holds on. That's exactly the behavior you'd want from a molecule meant to single out the inner mitochondrial membrane, and researchers treat this surface-electrostatics effect as a core part of how the peptide works rather than a side note.
Where the name comes from — the Szeto-Schiller family
In one line: "SS" stands for Szeto-Schiller, the two researchers behind a whole series of these small mitochondria-seeking peptides.
The "SS" prefix isn't a chemistry abbreviation — it credits Hazel Szeto and Peter Schiller, whose collaborative work produced a numbered series of cell-permeable, mitochondria-targeted peptides. SS-31 is simply the entry in that lineage to attract the most sustained study. In the formal research and clinical literature, the same molecule is usually called elamipretide; SS-31 and elamipretide are two names for the identical D-Arg–Dmt–Lys–Phe–NH2 structure.
That "family" framing matters for what comes next. Because Szeto, Schiller, and others built and compared many related sequences, there's a rich record of which structural features can be swapped, trimmed, or modified — and what happens to membrane binding when they are. That compare-the-analogs approach is what makes the structure-activity story tractable.
What researchers actually study SS-31 for
In one line: in the lab, the peptide is a tool for asking questions about mitochondrial membranes — studied in cell culture and animal models, never as a consumer product.
One precise point first: the items below describe what experiments have examined, not outcomes for any person. SS-31's interest comes from mitochondrial biology — bioenergetics, oxidative-stress, and cellular-signaling research — so that's the area where researchers reach for it. In cell-culture and animal-model studies, investigators have looked at whether the peptide's cardiolipin binding tracks with steadier cristae structure and supported ATP output, and at how it relates to reactive oxygen species and electron handling in the inner membrane (Marcucci et al., 2025). A separate strand of work has built novel analogs of the D-Arg–Dmt–Lys–Phe scaffold to probe which changes track with mitochondrial ATP synthesis in vitro (Wu et al., 2024).
Two more research directions round out the picture. Structure-activity relationship studies systematically vary the residues to map which parts of the tetrapeptide drive membrane binding, giving chemists a blueprint for future analogs (Szeto, 2022). And proteomic mapping has sketched a mitochondrial protein interaction landscape for SS-31, consistent with its inner-membrane localization. For anyone working with the compound at the bench, the practical questions are mundane but important — purity, identity, and handling and storage in the lab — because a small, modified peptide only behaves predictably when it's intact.
Frequently Asked Questions
What is SS-31 (elamipretide)?
SS-31, also called elamipretide, is a synthetic four-amino-acid peptide (D-Arg–Dmt–Lys–Phe–NH2) studied in laboratory settings for the way it concentrates inside mitochondria by binding the inner-membrane lipid cardiolipin. It is offered for research use only and is not a consumer product.
Why is SS-31 called a "mitochondria-targeted" peptide?
Because its chemistry steers it specifically to the inner mitochondrial membrane. A mix of positive charge and aromatic groups lets it bind cardiolipin, a phospholipid found almost exclusively there, so the peptide accumulates in mitochondria rather than spreading evenly through the cell.
What does the "SS" in SS-31 stand for?
SS refers to Szeto-Schiller, the two researchers whose lab developed this family of small mitochondria-targeted peptides. SS-31 is one numbered member of that series; elamipretide is the name used for the same compound in the research literature.
Is SS-31 the same as elamipretide?
Yes. SS-31 is the laboratory designation and elamipretide is the formal compound name; both refer to the same D-Arg–Dmt–Lys–Phe–NH2 tetrapeptide. Research-grade material is not equivalent to any approved pharmaceutical product of the same name.
Conclusion
Strip away the abbreviations and SS-31's "targeting" comes down to one elegant idea: build a small peptide that is half positive charge and half aromatic anchor, then aim it at cardiolipin — a lipid that lives almost nowhere except the inner mitochondrial membrane. Charge gets it close. The aromatic residues hold it there. The result is a molecule that piles up inside mitochondria far out of proportion to its size. Structure-activity work on the Szeto-Schiller family keeps refining that design, which is why SS-31 remains a useful lens for seeing how chemistry encodes destination. For related reading, the linked research explainers above are a good next stop.
For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.
Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.